Sen. Bernie Sanders announced a plan Monday to forgive the country's $1.6 trillion outstanding student loan tab, intensifying the higher education policy debate in the 2020...Personal Financeread more
"We do not seek conflict with Iran or any other country," Trump tells reporters in the Oval Office.Politicsread more
While earnings usually come in substantially ahead of expectations — as much as 4 or 5 percentage points is not unusual — the downward direction in the outlook doesn't speak...Earningsread more
Tech's hottest IPOs of the year, including Beyond Meat and Zoom, dropped on Monday, falling more than the broader market.Technologyread more
"We missed being the dominant mobile operating system by a very tiny amount. We were distracted during our antitrust trial. We didn't assign the best people to do the work,"...Technologyread more
PatientsLikeMe was bought by UnitedHealth following a review by Trump's Treasury Department, which scrutinized the start-up because it's backed by Chinese cash.Technologyread more
Some traders think the energy rally is about to wane, despite the sector being one of June's big winners.ETF Edgeread more
Stocks with this one feature are poised to crush the market after a rate cut, according to Goldman Sachs.Marketsread more
An Air Canada passenger traveling to Toronto from a weekend in Quebec City found herself stranded alone on the tarmac and in the dark, in what she described as a "nightmare."Airlinesread more
When Victoria's Secret exited the swimsuit business in 2016, it opened the floodgates for start-ups to conquer that market.Retailread more
Shopify debuts a new network to help it compete with Amazon.Marketsread more
A biotech spun out of Oxford University is aiming to develop a universal flu vaccine — and phase 2 trials could be completed by the end of next year.
The company, Vaccitech, says the vaccine — unlike those now found on the market — does not target surface antibodies. Instead, it works from the center of the virus where there are few components which can change the virus strain.
"It should protect people against pandemic strains and that would be hugely valuable to have," Vaccitech co-founder Adrian Hill told CNBC on Friday.
The company's approach to the flu is different from what many vaccine manufacturers have adopted, Hill said, adding that he hopes any Vaccitech success will make pharmaceutical giants take an interest and get involved.
Vaccitech's strategy has not been tested to work against the flu before, but Hill said his company has started trials involving thousands of people.
The tests mark one of the first times that a universal flu vaccine has progressed beyond phase 1 clinical testing and Vaccitech aims to complete phase 2B testing by the end of next year, he said.
Recently, the biotech start-up raised 20 million pounds (about $28 million) from investors including GV, the venture capital arm of Google parent Alphabet.
Vaccitech is also targeting two viruses that cause cancer — the human papillomavirus (HPV) and the hepatitis B virus.
"We are developing new vaccines again targeting cellular immunity that will go into the clinic in the next year or so to tackle those virus," Hill said.
HPV is known to cause cervical cancer and the hepatitis B virus infects hundreds of millions of people in Asia alone and is a major cause of liver cancer.
"If the cellular immunity approach works, there are a lot of potential targets," Hill said. "There are infections like HIV, where you can make a therapeutic HIV vaccine."
Correction: This article has been updated to reflect the state of testing on other universal flu vaccines.